Amorphous form of apremilast
US-9351957-B2 · May 31, 2016 · US
Forms of apremilast
US10730836B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10730836-B2 |
| Application number | US-201916555651-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 29, 2019 |
| Priority date | Jun 20, 2016 |
| Publication date | Aug 4, 2020 |
| Grant date | Aug 4, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure is directed to novel forms of apremilast and pharmaceutical compositions comprising any of the novel forms of apremilast. Also provided are processes for the preparation of novel forms of apremilast.
First claim
Opening claim text (preview).
What is claimed is: 1. Apremilast dimethylacetamide solvate Form I. 2. The apremilast dimethylacetamide solvate Form I according to claim 1 that has an X-ray powder diffraction pattern comprising peaks, in terms of 2-theta, at about 26.51 and about 17.93. 3. The apremilast dimethylacetamide solvate Form I according to claim 2 , further comprising peaks, in terms of 2-theta, at about 22.65, about 7.64, and about 24.96. 4. The apremilast dimethylacetamide solvate Form I according to claim 1 that is characterized by an endothermic event at about 129° C. 5. The apremilast dimethylacetamide solvate Form I according to claim 1 that is characterized by an endothermic event onset at about 126° C. 6. A composition comprising the apremilast dimethylacetamide solvate Form I according to claim 1 . 7. The composition according to claim 6 , wherein the composition is a pharmaceutical composition further comprising at least one pharmaceutically acceptable excipient. 8. A method of treating a disease selected from the group consisting of psoriatic arthritis, plaque psoriasis, and Behcet's disease comprising administering the pharmaceutical composition according to claim 7 to a subject in need thereof. 9. A method of making apremilast dimethylacetamide solvate Form I according to claim 1 , comprising exposing a starting material comprising apremilast to dimethylacetamide to yield apremilast dimethylacetamide solvate Form I.
Assignees
Inventors
Classifications
Crystalline forms, e.g. polymorphs · CPC title
- C07D209/48Primary
with oxygen atoms in positions 1 and 3, e.g. phthalimide · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10730836B2 cover?
- The present disclosure is directed to novel forms of apremilast and pharmaceutical compositions comprising any of the novel forms of apremilast. Also provided are processes for the preparation of novel forms of apremilast.
- Who is the assignee on this patent?
- Johnson Matthey Plc
- What technology area does this patent fall under?
- Primary CPC classification C07D209/48. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).